Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yoshiya Horimoto

Showing results (1-10 of 124) with videos related to

Pageof 13
Sort By:
Breast Cancer (Tokyo, Japan)|November 20, 2023
Comment on 'An increase in tumor-infiltrating lymphocytes after treatment is significantly associated with a poor response to neoadjuvant endocrine therapy for estrogen receptor-positive/HER2-negative breast cancers' by Fukui et alYoshiya Horimoto
Cancer Medicine|October 27, 2016
Pathology of healing: what else might we look at?Yoshiya Horimoto, Takuo Hayashi, Atsushi Arakawa
Breast Care (Basel, Switzerland)|November 7, 2018
Arthralgia in 329 Patients Taking Aromatase InhibitorsYoshiya Horimoto, Mitsue Saito, Fujio Kasumi
Breast Cancer (Tokyo, Japan)|February 20, 2013
Tumor lysis syndrome following trastuzumab for breast cancer: a case report and review of the literatureFumi Taira, Yoshiya Horimoto, Mitsue Saito
Surgical Case Reports|June 29, 2021
Metastatic breast tumors from extramammary malignancies: a case seriesRyoko Semba, Yoshiya Horimoto, Atsushi Arakawa, et al.
Cell Adhesion & Migration|May 10, 2012
Emerging roles of the tumor-associated stroma in promoting tumor metastasisYoshiya Horimoto, Urszula M Polanska, Yuko Takahashi, et al.
Cancers|November 13, 2013
Carcinoma-associated fibroblasts are a promising therapeutic targetShinsaku Togo, Urszula M Polanska, Yoshiya Horimoto, et al.
International Journal of Surgical Pathology|September 11, 2015
Ki67 Heterogeneity in Estrogen Receptor-Positive Breast Cancers: Which Tumor Type Has the Most Heterogeneity?Takanori Himuro, Yoshiya Horimoto, Atsushi Arakawa, et al.
Breast Cancer (Tokyo, Japan)|May 18, 2026
Limits of substitution and context-dependent selective omission of Oncotype DX recurrence score testingYoshiya Horimoto, Ryoko Semba, Takeshi Ushigusa, et al.
In Vivo (Athens, Greece)|February 27, 2019
Breast Cancer in Lean Postmenopausal Women Might Have Specific Pathological FeaturesToshitaka Uomori, Yoshiya Horimoto, Atsushi Arakawa, et al.
Pageof 13

Showing results (1-10 of 124) with videos related to

Sort By:
Pageof 13
Breast Cancer (Tokyo, Japan)|November 20, 2023
Comment on 'An increase in tumor-infiltrating lymphocytes after treatment is significantly associated with a poor response to neoadjuvant endocrine therapy for estrogen receptor-positive/HER2-negative breast cancers' by Fukui et alYoshiya Horimoto
Cancer Medicine|October 27, 2016
Pathology of healing: what else might we look at?Yoshiya Horimoto, Takuo Hayashi, Atsushi Arakawa
Breast Care (Basel, Switzerland)|November 7, 2018
Arthralgia in 329 Patients Taking Aromatase InhibitorsYoshiya Horimoto, Mitsue Saito, Fujio Kasumi
Breast Cancer (Tokyo, Japan)|February 20, 2013
Tumor lysis syndrome following trastuzumab for breast cancer: a case report and review of the literatureFumi Taira, Yoshiya Horimoto, Mitsue Saito
Surgical Case Reports|June 29, 2021
Metastatic breast tumors from extramammary malignancies: a case seriesRyoko Semba, Yoshiya Horimoto, Atsushi Arakawa, et al.
Cell Adhesion & Migration|May 10, 2012
Emerging roles of the tumor-associated stroma in promoting tumor metastasisYoshiya Horimoto, Urszula M Polanska, Yuko Takahashi, et al.
Cancers|November 13, 2013
Carcinoma-associated fibroblasts are a promising therapeutic targetShinsaku Togo, Urszula M Polanska, Yoshiya Horimoto, et al.
International Journal of Surgical Pathology|September 11, 2015
Ki67 Heterogeneity in Estrogen Receptor-Positive Breast Cancers: Which Tumor Type Has the Most Heterogeneity?Takanori Himuro, Yoshiya Horimoto, Atsushi Arakawa, et al.
Breast Cancer (Tokyo, Japan)|May 18, 2026
Limits of substitution and context-dependent selective omission of Oncotype DX recurrence score testingYoshiya Horimoto, Ryoko Semba, Takeshi Ushigusa, et al.
In Vivo (Athens, Greece)|February 27, 2019
Breast Cancer in Lean Postmenopausal Women Might Have Specific Pathological FeaturesToshitaka Uomori, Yoshiya Horimoto, Atsushi Arakawa, et al.
Pageof 13